Kenvue (FRA:J4D) FFO


FRA:J4D Kenvue Inc FRA:J4D
74 GF Score
Price €16.29
GF Value €17.35
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Kenvue FFO?

FFO (Funds from operations) only applies to REITs.

FRA:J4D
74GF Score
Kenvue Inc FRA:J4D
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Kenvue (FRA:J4D) Overvalued in 2026?

Based on GuruFocus' analysis, Kenvue stock appears to be undervalued. The current stock price of €16.29 is trading 6.1% below its estimated GF Value™ of €17.35. GuruFocus considers Kenvue to be Fairly Valued.

Key valuation signals for FRA:J4D:

  • FFO:
  • GF Value™: €17.35 vs. price of €16.29 (6.1% below fair value)
  • GF Score™: 74/100 with 6 warning signs

No single metric tells the full story. See the FRA:J4D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kenvue Business Description

Address 1 Kenvue Way, Summit, NJ, USA, 07901
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.
74GF Score

Get the complete analysis for FRA:J4D

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.29
Price
€17.35
GF Value